Advanced Search

BCL2 (S70A) Jurkat (ATCC® CRL-2900™)

Organism: Homo sapiens, human  /  Cell Type: T Cell/ T Lymphocyte  /  Tissue: peripheral blood  /  Disease: acute T cell leukemia

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type T Cell/ T Lymphocyte
Product Format frozen
Morphology lymphoid-like
Culture Properties suspension
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease acute T cell leukemia
Age 14 years
Gender male
Applications

This cell line is useful to study cell apoptosis, BCL-2 function and its pathway, as well as phosphorylation of BCL-2.
Storage Conditions liquid nitrogen vapor phase
Images CRL-2900 Micrograph
Derivation

The BCL2 (S70A) Jurkat cell line was derived by transfecting human Jurkat T cells with the pSFFV-neo mammalian expression vector containing the human BCL-2 mutated ORF insert and a neomycin-resistant gene (Parental vector: Addgene # 3349). Bcl2 (S70A) stable neomycin (Neo)-resistant single-cell originated clones were isolated and expanded by selection in medium containing 1 mg/mL G418 for 14 days.
Genes Expressed Neomycin resistance gene, expressed; BCL2 (S70A) mutant, over-expressed, verified at ATCC
Tumorigenic Yes
Comments

The BCL2 (S70A) Jurkat cell line was derived by transfecting human Jurkat T cells with the pSFFV-neo mammalian expression vector containing the human BCL2 mutated ORF insert and a neomycin-resistant gene (Parental vector: Addgene # 3349). The BCL2 (S70A) Jurkat cells contain the BCL2 ORF with a sub-mutation at Ser70, containing an amino-acid substitution to Ala70. BCL2 (S70A) stable neomycin (Neo)-resistant single-cell-originated clones were isolated and expanded by selection in medium containing 1 mg/mL G418 for 14 days. The BCL2 (S70A) Jurkat cell line over-expresses the S70A-mutated form of Bcl-2.

Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 10% FBS and 200 mcg/mL G418.
Subculturing

Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 x 105 viable cells/mL. Do not allow the cell density to exceed 3 x 106 cells/mL.

Subcultivation ratio:: Maintain cultures at a cell concentration between 1 x 105 and 1 X 106 viable cells/mL.
Medium renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation Freeze medium: 90% Fetal Bovine Serum and 10% DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
D5S818: 9
D13S317: 8, 12
D7S820: 8, 12
D16S539: 11
vWA: 18
TH01: 6, 9.3
Amelogenin: X Y
TPOX: 8, 10
CSF1PO: 11, 12
Name of Depositor Stanley Korsmeyer
Year of Origin 2003
References

Yamamoto K, et al. BCL-2 is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway normally Activated at G2/M. Mol Cell Biol. Dec;19(12):8469-78. 1999. PubMed: 10567572

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Other Documentation
Other Document
Cell Micrograph
References

Yamamoto K, et al. BCL-2 is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway normally Activated at G2/M. Mol Cell Biol. Dec;19(12):8469-78. 1999. PubMed: 10567572